title: Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions.
abstract: OBJECTIVE
  To report the final, cumulative, 5-year outcomes from the TAXUS ATLAS program, which studied the use of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions.
  
  
  METHODS
  TAXUS ATLAS Workhorse, Small Vessel, and Long Lesion are nonrandomized studies comparing TAXUS Liberté (N=871), TAXUS Liberté 2.25 mm (N=261), and TAXUS Liberté 38 mm (N=150) stents, respectively, with case-matched TAXUS Express historical controls.
  
  
  RESULTS
  In the unadjusted analysis, TAXUS Liberté showed comparable 5-year rates of major adverse cardiac events (27.1% TAXUS Express vs. 26.2% TAXUS Liberté, P=0.70) in workhorse lesions and greater 5-year cumulative freedom from target lesion revascularization (78.4 vs. 87.3%, P=0.03) in small vessels. In addition, a lower periprocedural myocardial infarction rate (MI, 4.1 vs. 0.0%; P=0.01) was observed in long lesions versus TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberté on the 5-year rates of TLR in small vessels (17.9 vs. 13.3%, P=0.36) or MI in long lesions (9.1 vs. 7.0%, P=0.53) was found, although the rates remained numerically lower with TAXUS Liberté.
  
  
  CONCLUSIONS
  Cumulative 5-year results of the TAXUS ATLAS studies suggest that the TAXUS Liberté stent provides similar safety and effectiveness in workhorse lesions, and may provide lower revascularization rates in small vessels and lower periprocedural MI rates in long lesions compared with the TAXUS Express stent, although no statistically significant differences were found following propensity adjustment.
authors.affiliation: Mercy Angiography Unit, Mercy Hospital, Epsom, Auckland 1003, New Zealand. johnorm@ihug.co.nz
authors.forename: John A
authors.initials: JA
authors.lastname: Ormiston
authors.forename: O'Shaughnessy
authors.initials: O
authors.lastname: Charles
authors.forename: Tift
authors.initials: T
authors.lastname: Mann
authors.forename: Jack J
authors.initials: JJ
authors.lastname: Hall
authors.forename: Thomas
authors.initials: T
authors.lastname: McGarry
authors.forename: Louis A
authors.initials: LA
authors.lastname: Cannon
authors.forename: Mark W I
authors.initials: MW
authors.lastname: Webster
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Mishkel
authors.forename: Paul L
authors.initials: PL
authors.lastname: Underwood
authors.forename: Keith D
authors.initials: KD
authors.lastname: Dawkins
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D001208:Asia; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D009203:Myocardial Infarction / Q000209:etiology; D009520:New Zealand; D017239:Paclitaxel / Q000008:administration & dosage*; D057216:Propensity Score; D011446:Prospective Studies; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel